AKT1 and cancer: Inhibition of PI3K/AKT/NF-κB pathway was a potential target for cancer treatment (Sha et al., 2014; Pickard et al., 2017; Mao et al., 2019; Lian et al., 2020; Ling et al., 2020; Sun et al., 2020; Zhang et al., 2020).